Moomoo AI 已提取核心信息
Arcutis Biotherapeutics, Inc. has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, as per a letter dated February 6, 2024. The company seeks to have the Registration Statement, with the number 333-276794, become effective by 4:00 p.m. Washington, D.C. time on February 8, 2024, or as soon as possible thereafter. This request was made under Rule 461 of the Securities Act of 1933, as amended. Arcutis has indicated that their counsel, Latham & Watkins LLP, may request a different effective time by phone. The company has asked the SEC to confirm the effectiveness of the Registration Statement orally with their counsel following its declaration.
Arcutis Biotherapeutics, Inc. has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, as per a letter dated February 6, 2024. The company seeks to have the Registration Statement, with the number 333-276794, become effective by 4:00 p.m. Washington, D.C. time on February 8, 2024, or as soon as possible thereafter. This request was made under Rule 461 of the Securities Act of 1933, as amended. Arcutis has indicated that their counsel, Latham & Watkins LLP, may request a different effective time by phone. The company has asked the SEC to confirm the effectiveness of the Registration Statement orally with their counsel following its declaration.
根据2024年2月6日的一封信，Arcutis Biotherapeutics, Inc.已正式要求美国证券交易委员会（SEC）加快其S-3表格注册声明的生效日期。该公司力求使编号为333-276794的注册声明在华盛顿特区时间2024年2月8日下午4点之前或之后尽快生效。该请求是根据经修订的1933年《证券法》第461条提出的。Arcutis表示，他们的律师瑞生和沃特金斯律师事务所可能会通过电话要求不同的生效时间。该公司已要求美国证券交易委员会在声明后与其律师口头确认注册声明的有效性。
根据2024年2月6日的一封信，Arcutis Biotherapeutics, Inc.已正式要求美国证券交易委员会（SEC）加快其S-3表格注册声明的生效日期。该公司力求使编号为333-276794的注册声明在华盛顿特区时间2024年2月8日下午4点之前或之后尽快生效。该请求是根据经修订的1933年《证券法》第461条提出的。Arcutis表示，他们的律师瑞生和沃特金斯律师事务所可能会通过电话要求不同的生效时间。该公司已要求美国证券交易委员会在声明后与其律师口头确认注册声明的有效性。
有用
没用